Page 942 - Adams and Stashak's Lameness in Horses, 7th Edition

908 Chapter 8

21. Clayton HM, Almeida PE, Prades M, et al. Double‐blind study of 45. Fenton JI, Chlebek‐Brown KA, Peters TL, et al. The effects of glu-
the effects of an oral supplement intended to support joint health cosamine derivatives on equine articular cartilage degradation in
explant culture. Osteoarthritis Cartilage 2000;8:444–451.
VetBooks.ir 22. Collins JA, Moots RJ, Clegg PD, et al. Resveratrol and N‐acetyl- 46. Fenton JI, Chlebek‐Brown KA, Peters TL, et al. Glucosamine HCl
in horses with tarsal degenerative joint disease. Proc Am Assoc
Equine Pract 2002;48:314–317.
reduces equine articular cartilage degradation in explant culture.
Osteoarthritis Cartilage 2000;8:258–265.
cysteine influence redox balance in equine articular chondrocytes
under acidic and very low oxygen conditions. Free Rad Biol Med
2015;86:57–64. 47. Foreman JH, Ruemmler R. Phenylbutazone and flunixin meglu-
mine used singly or in combination in experimental lameness in
23. Conte A, de Bernardi M, Palmieri L, et al. Metabolic fate of exog- horses. Equine Vet J 2011;43(Suppl 40):12–17.
enous chondroitin sulfate in man. Arzneimittelforschung 1991;41: 48. Fradette ME, Celeste C, Richard H, et al. Effects of continuous
768–772. oral administration of phenylbutazone on biomarkers of cartilage
24. Conte A, Volpi N, Palmieri L, et al. Biochemical and pharmacoki- and bone metabolism in horses. Am J Vet Res 2007;68:128–133.
netic aspects of oral treatment with chondroitin sulfate. 49. Frondoza CG, Fortuno LV, Grzanna MW, et al. α‐Lipoic acid poten-
Arzneimittelforschung 1995;45:918–925. tiates the anti‐inflammatory activity of avacavocadobean unsaponi-
25. Cotter GH, Riley WF, Beck CC, et al. Arquel (Cl‐1583). A new fiables in chondrocyte cultures. Cartilage 2018;9:304–312.
nonsteroidal anti‐inflammatory drug for horses. Proceedings Am 50. Gerstenfeld LC, Kelly CM, Von Deck M, et al. Effect of 1,25‐dihy-
Assoc Equine Pract 1973;19:81–90. droxyvitamin D3 on induction of chondrocyte maturation in cul-
26. Cox S, Villarino N, Sommardahl C, et al. Disposition of firocoxib ture: extracellular matrix gene expression and morphology.
in equine plasma after an oral loading dose and a multiple dose Endocrinology 1990;126:1599–1609.
regimen. Vet J 2013;198:382–385. 51. Goggs R, Vaughan‐Thomas A, Clegg PD, et al. Nutraceutical ther-
27. Cuniberti B, Odore R, Barbero R, et al. In vitro and ex vivo phar- apies for degenerative joint diseases: a critical review. Crit Rev
macodynamics of selected non‐steroidal anti‐inflammatory drugs Food Sci Nutr 2005;45:145–164.
in equine whole blood. Vet J 2012;191:327–333. 52. Grimm H, Mayer K, Mayser P, et al. Regulatory potential of n‐3
28. Curtis CL, Hughes CE, Flannery CR, et al. N‐3 fatty acids specifi- fatty acids in immunological and inflammatory processes. Br J
cally modulate catabolic factors involved in articular cartilage Nutr 2002;87(Suppl 1):S59–S67.
degradation. J Biol Chem 2000;275:721–724. 53. Gupta RC, Canerdy TD, Skaggs P, et al. Therapeutic efficacy of
29. Curtis CL, Harwood JL, Dent CM, et al. Biological basis for the undenatured type‐II collagen (UC‐II) in comparison to glucosa-
benefit of nutraceutical supplementation in arthritis. Drug Discov mine and chondroitin in arthritic horses. J Vet Pharmacol Ther
Today 2004;9:165–172. 2009;577–584.
30. D’Arcy‐Moskwa E, Noble GK, Weston LA, et al. Effects of melox- 54. Gustafson S, Bjorkman T. Circulating hyaluronan, chondroitin
icam and phenylbutazone on equine gastric mucosal permeability. sulphate and dextran sulphate bind to a liver receptor that does
J Vet Intern Med 2012;26:1494–1499. not recognize heparin. Glycoconj J 1997;14:561–568.
31. Davis LE, Westfall BA. Species differences in biotransformation 55. Hanson RR, Smalley LR, Huff GK, et al. Oral treatment with a
and excretion of salicylate. Am J Vet Res 1972;33:1253–1262. glucosamine‐chondroitin sulfate compound for degenerative joint
32. Dechant JE, Baxter GM, Frisbie DD, et al. Effects of glucosamine disease in horses: 25 cases. Equine Pract 1997;19:16–22.
hydrochloride and chondroitin sulphate, alone and in combina- 56. Hanson RR, Brawner WR, Blaik MA, et al. Oral treatment with a
tion, on normal and interleukin‐1 conditioned equine articular nutraceutical (Cosequin) for ameliorating signs of navicular syn-
cartilage explant metabolism. Equine Vet J 2005;37:227–231. drome in horses. Vet Ther 2001;2:148–159.
33. Derfoul A, Miyoshi AD, Tuan RS. Glucosamine promotes chon- 57. Henrotin YE, Sanchez C, Deberg MA, et al. Avocado/soybean
drogenic phenotype in both chondrocytes and mesenchymal stem unsaponifiables increase aggrecan synthesis and reduce catabolic
cells and inhibits IL‐1 beta induced MMP‐13 expression and and proinflammatory mediator production by human osteoar-
matrix degradation. Transactions of the 51st Annual Meeting of thritic chondrocytes. J Rheumatol 2003;30:1825–1834.
the Orthopaedic Research Society 2005:1477. 58. Higler MH, Brommer H, L’ami JJ, et al. The effects of three‐month
34. Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels oral supplementation with a nutraceutical and exercise on
of aggrecan and matrix metalloproteinase‐3 synthesized by cul- the locomotor pattern of aged horses. Equine Vet J 2014;46:
tured human osteoarthritis articular chondrocytes. Osteoarthritis 611–617.
Cartilage 2003;11:424–432. 59. Hoffer LJ, Kaplan LN, Hamadeh MJ, et al. Sulfate could mediate
35. Dorna V, Guerrero RC. Effects of oral and intramuscular use of the therapeutic effect of glucosamine sulfate. Metabolism
chondroitin sulfate in induced equine aseptic arthritis. J Equine 2001;50:767–770.
Vet Sci 1998;18:548–555. 60. Holland B, Fogle C, Blikslager AT, et al. Pharmacokinetics and
36. Doucet MY, Bertone AL, Hendrickson D, et al. Comparison of pharmacodynamics of three formulations of firocoxib in healthy
efficacy and safety of paste formulations of firocoxib and phe- horses. J Vet Pharmacol Ther 2014;38:249–256.
nylbutazone in horses with naturally occurring osteoarthritis. 61. Horvath K, Noker PE, Somfai‐Relle S, et al. Toxicity of methylsul-
J Am Vet Med Assoc 2008;232:91–97. fonylmethane in rats. Food Chem Toxicol 2002;40:1459–1462.
37. Du J, White N, Eddington ND. The bioavailability and pharma- 62. Houdeshell JW, Hennessey PW. A new non‐steroidal, anti‐inflam-
cokinetics of glucosamine hydrochloride and chondroitin sulfate matory analgesic for horses. J Equine Med Surg 1977;1:57–63.
after oral and intravenous single dose administration in the horse. 63. Hovanessian N, Davis JL, McKenzie HC, et al. Pharmacokinetics and
Biopharm Drug Dispos 2004;25:109–116. safety of firocoxib after oral administration of repeated consecutive
38. Duz M, Parkin TD, Cullander RM, et al. Effect of flunixin meglu- doses to neonatal foals. J Vet Pharmacol Ther 2013;37:243–251.
mine and firocoxib on ex vivo cyclooxygenase activity in horses 64. Howard RD, McIlwraith CW. Hyaluronan and its use in the treat-
undergoing elective surgery. Am J Vet Res 2015;76:208–215. ment of equine joint disease. In Joint Disease in the Horse, 1st ed.
39. Duz M, Marshall JF, Parkin TD. Proportion of nonsteroidal anti‐ McIlwraith CW, Trotter GW, eds. WB Saunders, Philadelphia,
inflammatory drug prescription in equine practice. Equine Vet J 1996;257–269.
2019;51:147–153. 65. Humphries DE, Silbert CK, Silbert JE. Glycosaminoglycan pro-
40. Eddington ND, Du J, White N. Evidence of the oral absorption of duction by bovine aortic endothelial cells cultured in sulfate‐
chondroitin sulfate as determined by total disaccharide content depleted medium. J Biol Chem 1986;261:9122–9127.
after oral and intravenous administration to horses. Proc Am 66. Iguchi K, Okumura N, Usui S, et al. Myristoleic acid, a cytotoxic
Assoc Equine Pract 2001;47:326–328. component in the extract from Serenoa repens, induces apoptosis
41. Elmali N, Baysal O, Harma A, et al. Effects of resveratrol in and necrosis in human prostatic LNCaP cells. Prostate 2001;47:
inflammatory arthritis. Inflammation 2007;30:1–6. 59–65.
42. Evans MS, Reid KH, Sharp JB Jr. Dimethylsulfoxide (DMSO) 67. Ilic MZ, Martinac B, Handley CJ. Effects of long‐term exposure to
blocks conduction in peripheral nerve C fibers: a possible mecha- glucosamine and mannosamine on aggrecan degradation in artic-
nism of analgesia. Neurosci Lett 1993;150:145–148. ular cartilage. Osteoarthritis Cartilage 2003;11:613–622.
43. FDA‐CVM. Freedom of Information Summary. EQUIOXX Oral 68. Johansson IM, Kallings P, Hammarlund‐Udenaes M. Studies of
Paste‐0.82% Firocoxib (w/w). FDA NADA, Rockville, MD, meclofenamic acid and two metabolites in horses—pharmaco‐
2005;141–253. kinetics and effects on exercise tolerance. J Vet Pharmacol Ther
44. Fenton JI, Orth MW, Chlebek‐Brown KA, et al. Effect of lunging 1991;14:235–242.
and glucosamine supplementation on serum markers of bone and 69. Jones EW, Hamm D. Comparative efficacy of phenylbutazone and
joint metabolism in yearling Quarter horses. Can J Vet Res naproxen in induced equine myositis. J Equine Med Surg 1978;2:
1999;63:288–291. 341–347.